About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Joaquin Seras Franzoso Collaborators: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats Funding agency: Instituto de Salud Carlos III Funding: 99220 Reference: PI22/01301 Duration: 01/01/2023 - 31/12/2025
IP: Maria Jose Soler Romeo Collaborators: Francesc Moreso Mateos, Oriol Bestard Matamoros, Joana Sellarés Roig, Irina Betsabe Torres Rodriguez, Concepció Jacobs Cachá, Maria Antonia Emilia Meneghini Funding agency: Instituto de Salud Carlos III Funding: 105765 Reference: RD21/0005/0016 Duration: 01/01/2022 - 31/12/2024
IP: Francisco Rodríguez Frias Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 82400 Reference: FI19/00025 Duration: 23/01/2020 - 22/01/2024
IP: Ibane Abasolo Olaortua Collaborators: Fernanda Raquel Da Silva Andrade, Miriam Izquierdo Sans Funding agency: Asociación Española Contra el Cáncer Funding: 100000 Reference: INVES211530DASI Duration: 01/09/2021 - 31/08/2025
PMID: 37952070 Journal: Internal and Emergency Medicine Year: 2023 Reference: Intern Emerg Med. 2023 Nov 11. doi: 10.1007/s11739-023-03441-2. Impact factor: Publication type: Paper in international publication Authors: Abrisqueta, Pau; Augustin, Salvador; Campo, Elias; Casanueva-Eliceiry, Sebastian; Ciudin, Andreea; Correa, Juan Gonzalo; Delgado, Julio; Ferrer-Costa, Roser; Gabriel-Medina, Pablo; Gine, Eva et al. DOI: 10.1007/s11739-023-03441-2
PMID: 37963304 Journal: JOURNAL OF CLINICAL ONCOLOGY Year: 2023 Reference: J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339. Impact factor: Publication type: Paper in international publication Authors: Agarwal, Neeraj; Augustin, Salvador; Barnicle, Alan; Chi, Kim N; Ciudin, Andreea; de Bono, Johann S; Ferrer-Costa, Roser; Fizazi, Karim; Gabriel-Medina, Pablo; Hussain, Maha et al. DOI: 10.1200/JCO.23.00339
PMID: 37964360 Journal: BREAST CANCER RESEARCH Year: 2023 Reference: Breast Cancer Res. 2023 Nov 14;25(1):143. doi: 10.1186/s13058-023-01736-y. Impact factor: Publication type: Paper in international publication Authors: Baulida, Josep; Benitez-Carbante, Maria Isabel; Diaz de Heredia, Cristina; Eyras, Eduardo; Fernandez Ledesma, Berta; Fernandez-Polo, Aurora; Franco-Valls, Hector; Garcia de Herreros, Antonio; Grau Cerrato, Santiago; Iaconcig, Alessandra et al. DOI: 10.1186/s13058-023-01736-y
PMID: 37996255 Journal: ANNALS OF CLINICAL BIOCHEMISTRY Year: 2023 Reference: Ann Clin Biochem. 2023 Nov 23:45632231219387. doi: 10.1177/00045632231219387. Impact factor: Publication type: Paper in international publication Authors: Andrade, Monica Viegas; Blanco, Albert; Bracarense, Henrique; Braga, Paulo Estevao Franco; Comas, Immaculada; Conesa, Laura; de Miranda, Maria Carolina Correa; de Souza, Aline; Diaz-Troyano, Noelia; Ferrer, Roser et al. DOI: 10.1177/00045632231219387
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.
